AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Shareholders of AngioDynamics, Inc. (NASDAQ:ANGO) will be pleased this week, given that the stock price is up 13% to US$6.95 following its latest yearly results. The business exceeded expectations with revenue of US$304m coming in 3.8% ahead of forecasts. Statutory losses were US$4.59 a share, in line with what the analysts predicted. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

See our latest analysis for AngioDynamics

Taking into account the latest results, the three analysts covering AngioDynamics provided consensus estimates of US$284.4m revenue in 2025, which would reflect a noticeable 6.4% decline over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 82% to US$0.81. Before this earnings announcement, the analysts had been modelling revenues of US$287.2m and losses of US$1.19 per share in 2025. Although the revenue estimates have not really changed AngioDynamics'future looks a little different to the past, with a very favorable reduction to the loss per share forecasts in particular.

The average price target held steady at US$13.33, seeming to indicate that business is performing in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on AngioDynamics, with the most bullish analyst valuing it at US$14.00 and the most bearish at US$13.00 per share. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that revenue is expected to reverse, with a forecast 6.4% annualised decline to the end of 2025. That is a notable change from historical growth of 5.0% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 8.2% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - AngioDynamics is expected to lag the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that AngioDynamics' revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for AngioDynamics going out to 2027, and you can see them free on our platform here.

It is also worth noting that we have found 2 warning signs for AngioDynamics that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com